Bram Vanparys has a successful track record in life science investing and was instrumental in the formation, financing and/or exit of several start-ups across Europe, US and Israel, including arGEN-X (ARGX:EBR), Imcheck (acquired by Ipsen), Calypso Biotech (acquired by Novartis), Multiplicom (acquired by Agilent), Cartagenia (acquired by Agilent), Q-Biologicals (acquired by Amatsigroup, now Eurofins).